AGRIFLU 15 MCG / 0.5 ML
HAEMAGGLUTININ-STRAIN A (H3N2) : 15 MCG / 0.5 ML HAEMAGGLUTININ-STRAIN B : 15 MCG / 0.5 ML HAEMAGGLUTININ-STRAIN A (H1N1) : 15 MCG / 0.5 ML · DIN 02428881 · SEQIRUS UK LIMITED
Health Canada status: CANCELLED PRE MARKET
What is AGRIFLU?
AGRIFLU 15 MCG / 0.5 ML contains HAEMAGGLUTININ-STRAIN A (H3N2) : 15 MCG / 0.5 ML HAEMAGGLUTININ-STRAIN B : 15 MCG / 0.5 ML HAEMAGGLUTININ-STRAIN A (H1N1) : 15 MCG / 0.5 ML. It is listed in the Health Canada Drug Product Database under DIN 02428881, held by SEQIRUS UK LIMITED, supplied as SUSPENSION for INTRAMUSCULAR administration. Health Canada currently lists it as cancelled pre market, status dated 15-Jun-2022. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02428881 |
|---|---|
| Brand name | AGRIFLU |
| Generic / active ingredient | HAEMAGGLUTININ-STRAIN A (H3N2) : 15 MCG / 0.5 ML HAEMAGGLUTININ-STRAIN B : 15 MCG / 0.5 ML HAEMAGGLUTININ-STRAIN A (H1N1) : 15 MCG / 0.5 ML |
| Manufacturer | SEQIRUS UK LIMITED |
| Strength | 15 MCG / 0.5 ML |
| Dosage form | SUSPENSION |
| Route of administration | INTRAMUSCULAR |
| Schedule | Schedule D |
| ATC code | J07BB02 INFLUENZA, INACTIVATED, SPLIT VIRUS OR SURFACE ANTIGEN |
| AHFS class | 80:12.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED PRE MARKET |
| Status date | 15-Jun-2022 |
| Original market date | 2015-10-09 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code J07BB02 INFLUENZA, INACTIVATED, SPLIT VIRUS OR SURFACE ANTIGEN. 8 of 36 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AREPANRIX H5N1 | 3.75 MCG / 0.5 ML | EMULSION | ID BIOMEDICAL CORPORATION OF QUEBEC | MARKETED | DIN 02401886 |
| FLUAD | 15 MCG / 0.5 ML | SUSPENSION | SEQIRUS UK LIMITED | MARKETED | DIN 02362384 |
| FLUCELVAX | 15 MCG / 0.5 ML | SUSPENSION | SEQIRUS UK LIMITED | MARKETED | DIN 02553708 |
| FLUVIRAL | 15 MCG / 0.5 ML | SUSPENSION | ID BIOMEDICAL CORPORATION OF QUEBEC | MARKETED | DIN 02420686 |
| FLUZONE | 15 MCG / 0.5 ML | SUSPENSION | SANOFI PASTEUR LIMITED | MARKETED | DIN 02365936 |
| FLUZONE | 15 MCG / 0.5 ML | SUSPENSION | SANOFI PASTEUR LIMITED | MARKETED | DIN 02365707 |
| FLUZONE HIGH-DOSE | 60 MCG / 0.5 ML | SUSPENSION | SANOFI PASTEUR LIMITED | MARKETED | DIN 02445646 |
| INFLUVAC TETRA | 15 MCG / 0.5 ML | SUSPENSION | BGP PHARMA ULC | MARKETED | DIN 02484854 |
| AFLURIA TETRA | 15 MCG / 0.5 ML | SUSPENSION | SEQIRUS PTY LTD | CANCELLED POST MARKET | DIN 02473283 |
| AFLURIA TETRA | 15 MCG / 0.5 ML | SUSPENSION | SEQIRUS PTY LTD | CANCELLED POST MARKET | DIN 02473313 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.